- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 277/32 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 277/32
Total number of patents in this class: 146
10-year publication summary
8
|
13
|
13
|
10
|
7
|
7
|
3
|
3
|
7
|
2
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
BASF SE | 20458 |
11 |
Sumitomo Chemical Company, Limited | 8997 |
8 |
Syngenta Participations AG | 3029 |
5 |
Georgia Tech Research Corporation | 2623 |
4 |
Bayer Cropscience AG | 2136 |
3 |
Abbvie Inc. | 1785 |
3 |
The Board of Trustees of the University of Illinois | 2668 |
3 |
Nissan Chemical Industries, Ltd. | 1756 |
3 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 806 |
3 |
Mitsui Chemicals Crop & Life Solutions,Inc. | 149 |
3 |
Allergan, Inc. | 2431 |
2 |
Wisconsin Alumni Research Foundation | 3838 |
2 |
Takeda Pharmaceutical Company Limited | 2945 |
2 |
Arkema Inc. | 1071 |
2 |
East China University of Science and Technology | 496 |
2 |
FMC Corporation | 850 |
2 |
Gifu University | 137 |
2 |
Kissei Pharmaceutical Co., Ltd. | 198 |
2 |
Korea Research Institute of Chemical Technology | 1342 |
2 |
MedImmune Limited | 622 |
2 |
Other owners | 80 |